Beneficial antipruritic effects of lowering Interleukin -17 and/or IgE by anti-IgE monoclonal antibodies and PPAR gamma agonist in experimentally induced atopic dermatitis in mice
Ragab, M., Abdallah, W., Addel Maksoud, R., Nasser, D., El Azhary, N. (2022). Beneficial antipruritic effects of lowering Interleukin -17 and/or IgE by anti-IgE monoclonal antibodies and PPAR gamma agonist in experimentally induced atopic dermatitis in mice. EKB Journal Management System, 42(1), 63-73. doi: 10.21608/besps.2021.82025.1104
Magdy Ragab; Wafaa Abdallah; Rania El Saied Addel Maksoud; Dina Ragheb Nasser; Nesrine El Azhary. "Beneficial antipruritic effects of lowering Interleukin -17 and/or IgE by anti-IgE monoclonal antibodies and PPAR gamma agonist in experimentally induced atopic dermatitis in mice". EKB Journal Management System, 42, 1, 2022, 63-73. doi: 10.21608/besps.2021.82025.1104
Ragab, M., Abdallah, W., Addel Maksoud, R., Nasser, D., El Azhary, N. (2022). 'Beneficial antipruritic effects of lowering Interleukin -17 and/or IgE by anti-IgE monoclonal antibodies and PPAR gamma agonist in experimentally induced atopic dermatitis in mice', EKB Journal Management System, 42(1), pp. 63-73. doi: 10.21608/besps.2021.82025.1104
Ragab, M., Abdallah, W., Addel Maksoud, R., Nasser, D., El Azhary, N. Beneficial antipruritic effects of lowering Interleukin -17 and/or IgE by anti-IgE monoclonal antibodies and PPAR gamma agonist in experimentally induced atopic dermatitis in mice. EKB Journal Management System, 2022; 42(1): 63-73. doi: 10.21608/besps.2021.82025.1104

Beneficial antipruritic effects of lowering Interleukin -17 and/or IgE by anti-IgE monoclonal antibodies and PPAR gamma agonist in experimentally induced atopic dermatitis in mice

Bulletin of Egyptian Society for Physiological Sciences
Article 6, Volume 42, Issue 1, January 2022, Pages 63-73    PDF (566.37 K)
Document Type: Original Article
DOI: 10.21608/besps.2021.82025.1104
Authors
Magdy Ragab1; Wafaa Abdallah2; Rania El Saied Addel Maksoud1; Dina Ragheb Nasser3; Nesrine El Azhary* 4
1Department of Dermatology, Venerology and Andrology; Faculty of Medicine, University of Alexandria, Egypt
2Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Alexandria University, Egypt
3Egyptian Ministry of Health Hospitals
4Department of Medical Physiology, Faculty of Medicine, Alexandria University, Egypt
Abstract
Introduction: Itch is a major complaint in chronic allergic dermatitis. High levels of interleukin -17 (IL -17) and immunoglobulin E (Ig E) have been suspected to play a major role in this inflammatory condition. The aim of this work was to study the potential antipruritic effect of lowering IL-17 and /or IgE by anti IgE monoclonal antibodies and peroxisome proliferator-activated receptor gamma (PPAR γ) agonist in an experimental model of atopic dermatitis (AD) induced by oxazolone in mice. Methods: Fifty female mice were randomly assigned to 4 groups. AD-like lesions were induced in group 2, 3 and 4 by application of 5 % oxazolone followed by 0.1% oxazolone to the mice skin (chronic AD). Group 2 mice were left untreated while those in group 3 and 4 received anti IgE monoclonal antibodies (omalizumab) and PPAR γ agonist (pioglitazone) respectively. Results: Administration of either anti IgE monoclonal antibodies (omalizumab) and PPAR γ agonist (pioglitazone) significantly reduced scratching behavior in treated mice. This was accompanied by significant decrease of the elevated levels of IL-17 and IgE by both drugs. IL-17 suppression was better with pioglitazone while IgE suppression was more significant with omalizumab. Dermoscopic, histological examination and transepidermal water loss (TEWL) also showed significant improvement. Conclusions: Both anti IgE monoclonal antibodies (omalizumab) and PPAR γ agonist (pioglitazone) offer antipruritic effects in AD by reducing IL-17, Ig E and transepidermal water loss.
Keywords
Antipruritic; AntiIgE; PPARγ agonists
Statistics
Article View: 210
PDF Download: 214